Announcing the MAGIC-ONC guidelines for the placement and management of vascular access devices in patients with cancer, including specific recommendations for both hematologic and solid tumor malignancies. #MAGICOnc #oncsky #medsky www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social

Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm. Thanks David Russler-Germain + collabs aacrjournals.org/clincancerre...

An important step forward in improving vascular access safety for patients with cancer, introducing the MAGIC-ONC guidelines! www.acpjournals.org/doi/epdf/10....

Woah! @majorajay.bsky.social thinking through just about every hematology/oncology vascular access question possible (1422 scenarios, to be exact) to guide access choice. #medsky #oncsky #nursesky Just a few examples below:

Late night publication (finally!) of our MAGIC-ONC appropriateness guidelines for vascular access in patients with cancer, now in @annalsofim.bsky.social. More to come tomorrow! #medsky #oncsky www.acpjournals.org/doi/full/10....

Dr. Valerie Crabtree @stjude.bsky.social presented the findings of our qualitative study of patient and care partner perspectives in NLPHL at @worldsiop.bsky.social #SIOPCongress. Read our study here: pubmed.ncbi.nlm.nih.gov/40059593/ #lymsm cc @cucancercenter.bsky.social @cuanschutz.bsky.social

This morning's meeting of our monthly @accordsresearch.bsky.social imPROve Patient-Reported Outcomes Working Group. Phenomenal group of @cuanschutz.bsky.social @cucancercenter.bsky.social investigators working on new quality of life studies. #HRQoL medschool.cuanschutz.edu/accords/rese...

RW pola outcomes by Hans COO @eddiecliff.bsky.social - 740 pts, 59% R/R - R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC - 1L: no diff in outcomes Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm aacrjournals.org/clincancerre...

The first report of quality of life in patients with NLPHL from our ongoing NLPHLPRO multicenter trial (NCT06098430), presented by Dr. Jones at #ISCAYAHL. Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social

Interested in adding PROs to your study, or developing a quality of life project? Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky medschool.cuanschutz.edu/accords/rese...

CAR-T in PCNSL #lymsm - 67 pts, 25% CSF+, 12% eye+ - 57% axicel, 30% tisacel - 58% CR, 1-yr PFS 50%, OS 66% - 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28% - 27% G3+ ICANS! Almost all got bridging; would love to know which agents. academic.oup.com/neuro-oncolo...

Patient- vs clinician-reported AEs from POLARIX @bloodjournals.hematology.org: - symptom incidence & severity much higher measured by PROs - sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm) We must measure PROs in #lymsm trials! ashpublications.org/blood/articl...

CNS penetration of pola @bloodadvances.bsky.social - 3 pts (1 PCNSL, 2 SCNSL): 2 had CR (although these pts received IT chemo & ibrutinib, respectively) - pola detected in CSF of CNSL & systemic LBCL pts Provocative but unclear about single-agent activity. #lymsm ashpublications.org/bloodadvance...

Happy ASH abstract notification day! Looking forward to all your posters and orals in just a few months. #ASH25 @ash.hematology.org

Childhood cancer survivors face higher mortality after colorectal secondary cancers, with 50% diagnosed before age 40. Our new JNCI manuscript highlights need for tailored screening guidelines. #medsky #oncsky #survonc academic.oup.com/jnci/advance...

Survival after incidental vs symptomatic FL: - 908 pts, 29% incidental - incidental: more early stage & normal LDH - no diff in EFS, lymphoma-specific survival, or OS between groups We can answer the "what if this was picked up earlier" question! #lymsm www.nature.com/articles/s41...

Is this my brand now, ASH?! Very honored to receive this award! 🤣😂 #ASHCRTI @ash.hematology.org

Dr. Susie Curtis: "Grants are like blood clots; you're more likely to get one if you've already had one." #medsky #ASHCRTI @ash.hematology.org

Our CRTI group PROs and Poop! 💩 (intersection of patient-reported outcomes and fecal microbiome) #ASHCRTI cc @ash.hematology.org @biostatgirl.bsky.social

Day 1 of @ash.hematology.org CRTI! Super excited to learn from all these phenomenal investigators and faculty this week. #medsky #ASHKudos

Congratulations to Dr. Ogamba and this phenomenal group of investigators on execution of this large patient-reported outcomes study! And many thanks for the opportunity to contribute our PRO & financial toxicity methodologic expertise. #gyncsm #gynonc #medsky #oncsky www.nature.com/articles/s41...

Bispecifics in R/R LBCL @bloodjournals.hematology.org: - 245 pts, 64% epcor, 60% CAR - mPFS 2.5 mos (!!!): 2.3 epcor, 3.8 glofi - mOS 7.8 mos overall (in MV model, glofi = better OS) - worse PFS/OS if trial ineligible & w/i 90 d of CAR Outcomes not great. #lymsm ashpublications.org/blood/articl...

No more REMS for FDA-approved CAR-T products! Also, labeling updated for only 2 weeks in proximity to CAR center and 2 weeks no driving. #lymsm #tcellrx #mmsm www.fda.gov/vaccines-blo...

TP53mut 1L CLL zanu SEQUOIA #18ICML - 111 pts, med age 71 - 5-yr PFS 72%, OS 85% - 5% G5 AEs (not specified) - 33% G3+ infx Great PFS for TP53mut disease. My preferred option for patients. #lymsm

5-yr f/u CLL13/GAIA #18ICML - best PFS with GIV (5-yr 81%) - uIGHV with worse PFS with GV (5-yr 59%) vs GIV (76%) - no diff in OS between all 4 arms - more infx & cardiac AEs with GIV vs GV With uIGHV may consider acala/ven/obinu per AMPLIFY (or just good ol' GV). #18ICML #lymsm

inMIND tafa-R2 RCT in R/R FL #18ICML - 548 pts, 50% FLIPI 3-5, 32% POD24 - mPFS 22 mos (v 14 mos) with tafa - benefit seen with tafa in POD24 subgroup - superior TTNT, no diff OS, more deaths pbo arm - no HT events with tafa, multiple seen w/ pbo Now FDA approved in FL! #lymsm

Mosun in 1L FL #18ICML - 76 pts, ORR 95%, CR 82% - 1-yr PFS 89%, OS 99% - CRS mostly G1, 3% req'd hospitalization for infx - 1 death d/t COVID during tx Looking forward to longer f/u. #lymsm #tcellrx

Ph3 ibru-R v placebo-R in 1L FL #18ICML - 445 pts, med age 75 - PFS superior with ibr (altho not that much better vs R mono), no OS difference (although ibru OS curve worse!) - 15% G5 AEs (!!!) in ibru arm Way too toxic (and indefinite tx) in an indolent disease. #lymsm

Outcomes Stage IA NLPHL: superior PFS (not OS) for RT after complete resection (vs observation). For unresected patients, best PFS with RT & RT+ABVD, no diff OS. No diff in transformation events. More numerical SPMs after RT. #lymsm #18ICML

EBV+ pts in S1826 had much better PFS with nivo-AVD, although age & IPS differences between EBV+/- cohorts. Non-NS histologies also had much better PFS with nivo. #18ICML #lymsm

One of the longest follow-up studies I've seen in DLBCL. Excess mortality from infection remains higher than general population for greater than 10 years. AML/MDS highest 1-4 yrs, lung & GI cancers 5-25 yrs. Cardiac deaths have fallen over time. #18ICML #lymsm

Stathis et al - feasibility of PET & ctDNA response adaptation in 1L DLBCL. • operationally deliverable with ctDNA turnaround median 9d • low rate PET+ and ctDNA+ at interim • assessing whether acala addition benefits those with Myd88 &/or CD79b mutns SAKK38/19 trial #ICML18

PROs from BRUIN-321 pirto vs idelaR/BR R/R CLL #18ICML - pirto: better improvements in CLL-related sx, physical function, fatigue, all clinically significant - 83% PRO completion pirto at week 25, only 59% other arm Grain of salt given PRO dropout, but well reported. #lymsm

Accelerated ven ramp-up in CLL #18ICML - 40 pts, nearly all +obinu, most low TLS risk - 5-day daily escalation to 400 mg inpatient - only one high risk pt had lab TLS Obinu debulking before ven definitely helps. Maybe less time toxicity vs weekly ramp-up visits? #lymsm

We stan bridging RT before CAR! #18ICML - 116 pts with comprehensive RT to all PET avid sites - higher RT dose = less post-CAR G3+ CRS - higher LDH after RT = more G3+ CRS/ICANS Who else is using multisite bridging RT before CAR? #lymsm #tcellrx

>1500 trial & @cibmtr.bsky.social pts who received liso-cel: - 96-97% of CRS events were before D+15 - 88-95% ICANS before D+15 - no G5 CRS/ICANS after D+15 Do we really need a full 30 days of monitoring after liso-cel? #lymsm #tcellrx #18ICML

Pola bridging to CAR #18ICML - 200 pts: 122 polaBR, rest polaR - no diff in pre-CAR ORR with polaBR v polaR - more heme tox with BR - more ICANS w/ BR? tl;dr polaR just fine for bridging. #lymsm #tcellrx

CD19 CAR in SOT PTLD #18ICML - 12 pts, mostly kidney, most on steroids alone or nothing for IS - mPFS/mOS both 17 mos - all had CRS (2 Gr 3-4), 7 ICANS (2 Gr5!) - 1 graft failure Activity but seems toxic. No mention of product (axi-cel?) #lymsm #tcellrx

5-yr f/u trial of BV-AVD in HIV+ cHL: - 41 pts, majority Stage 3-4 - 5-yr PFS 78%, OS 89% - much more Gr3 neutropenia (but not NF), also more neuropathy - 7.6% tx/dx mortality at 5 yrs Great option; we have been using nivo-AVD as well. #lymsm #18ICML

Ph3 Pola +/- RGemOx R/R LBCL #18ICML - 255 pts, 66% primary refractory - superior OS & PFS w/ Pola - 12% (!!!) Gr5 AEs w/ Pola (4% in control) - 23% dc'd d/t AEs w/ Pola Quite toxic despite OS benefit. #lymsm

SAKK 38/19 1L DLBCL ctDNA-adapted acala + RCHOP #18ICML. Provocative trial design demonstrating feasibility of rapid mutational profiling (majority in 9 days) for targeted frontline therapies and also interim assessments. #lymsm

From @dgermain21.bsky.social #18ICML plenary: TEX (T exhausted) phenotype did not derive benefit from CAR-T in ZUMA-7. Super-exhausted macrophages appear to drive T-cell exhaustion in TEX. A subgroup which shouldn't get CAR? #18ICML #lymsm #tcellrx @icmlugano.bsky.social

Beautiful day at @icmlugano.bsky.social #18ICML! #lymsm

Dr. Dreyling's algorithm for older adults with MCL. Advocates for BR+acala in high-risk patients. We use a lot of acala+R in low-risk or unfit patients. #lymsm #18ICML @icmlugano.bsky.social

Dr. Dreyling's algorithm for management of fit MCL. Tricky part is lack of ibrutinib availability in this setting, but many of us have been using 2nd-gen BTKis. #lymsm #18ICML @icmlugano.bsky.social

Dr. Ferrero's algorithm for high risk MCL. Chemo-free regimens like acala+ritux or BOVen. If MRD positive, frequent monitoring for clinical relapse. #18ICML #lymsm @icmlugano.bsky.social

MRD positivity in MCL at 2 year landmark timepoint = very high risk of relapse. I routinely do MRD in MCL after 1L induction. #lymsm #18ICML

There are typical SOX11+ MCL cases which behave indolently (and could be observed). There is a specific gene signature of these cases, but not available mainstream. #18ICML #lymsm

You can observe advanced-stage NLPHL just like other indolent lymphomas. No compromised PFS2 for patients who are initially observed. And only 1/3 of patients needed treatment. #18ICML #lymsm

Wonderful to see the LP-IPS score mentioned in the #18ICML NLPHL session! Congratulations to Drs. Binkley and Flerlage and everyone at GLOW. Paper from JCO is here: ascopubs.org/doi/abs/10.1... #lymsm